Daiichi Sankyo's ADC portfolio consists of eight ADCs in clinical development, with seven ADCs in the DXd technology platform where ENHERTU and DATROWAY are jointly developed with AstraZeneca, and other candidates jointly developed with Merck & Co. The company has strategically pivoted away from diversified pharmaceutical portfolios to concentrate on oncology innovation and next-generation cancer therapeutics.
Cyborg Score Rationale
Daiichi Sankyo demonstrates strong competitive positioning in oncology through differentiated ADC technology and strategic partnerships with leading pharma companies. Recent FDA Priority Review for DATROWAY and ongoing clinical trials for novel candidates indicate robust pipeline momentum and commercial potential.
Top Insights
DATROWAY received Priority Review from the FDA as a first-line treatment for metastatic triple negative breast cancer patients not candidates for immunotherapy, based on improved overall survival versus chemotherapy in TROPION-Breast02
DS3790, a potential first-in-class CD37-directed DXd antibody drug conjugate discovered by Daiichi Sankyo, has dosed its first patient in a phase 1/2 trial for relapsed/refractory B-cell non-Hodgkin lymphoma
Strategic focus on oncology following divestiture of non-core pharmaceutical assets to Japan's Alfresa Holdings, enabling resource concentration on high-value ADC development
The company's market value rose above JPY 5 trillion in January 2020 following FDA approval of ENHERTU, developed with AstraZeneca who agreed to pay up to $6.9 billion for sales share
Named Competitors
ENHERTU — HER2-directed antibody-drug conjugate for breast cancer